When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Genmab A/S (OTCPK:GNMSF-20%) slumps on the news that collaboration partner Johnson & Johnson (JNJ-1.2%) has scrapped an early-stage study assessing the combination of DARZALEX (daratumumab) + Roche's TECENTRIQ (atezolizumab) in second-line lung cancer due to lack of efficacy and a safety signal, specifically an imbalance of deaths compared to placebo.
More news on: Genmab A/S, Johnson & Johnson, Healthcare stocks news, Stocks on the move,